Literature DB >> 23355939

Bone turnover markers in patients with type 1 Gaucher disease.

Gaetano Giuffrida1, Maria Rocca Cingari, Nunziatina Parrinello, Alessandra Romano, Anna Triolo, Magda Franceschino, Francesco Di Raimondo.   

Abstract

Bone complications occur frequently in Gaucher disease (GD) and reduce the quality of life of these patients. Skeletal involvement is an important indication for treatment to ameliorate symptoms and reduce the risk of irreversible and debilitating disease. Bone biomarkers have been used to assess disease status and the response to therapy in a number of bone disorders. Here, we examine the literature for evidence of abnormalities in bone turnover markers in patients with type 1 GD to assess whether they might be useful for the assessment of bone involvement in GD. We have found that bone biomarkers in GD show highly variable results which do not currently support their routine use for clinical assessment of bone status, as an indication for therapy initiation, or for monitoring the response to therapy. A greater understanding of bone markers and their relation to the bone manifestations of GD is required.

Entities:  

Keywords:  Gaucher disease; biomarkers; bone; osteopenia.

Year:  2012        PMID: 23355939      PMCID: PMC3555209          DOI: 10.4081/hr.2012.e21

Source DB:  PubMed          Journal:  Hematol Rep        ISSN: 2038-8322


  55 in total

Review 1.  Inflammatory bone loss: pathogenesis and therapeutic intervention.

Authors:  Kurt Redlich; Josef S Smolen
Journal:  Nat Rev Drug Discov       Date:  2012-03-01       Impact factor: 84.694

2.  Early achievement and maintenance of the therapeutic goals using velaglucerase alfa in type 1 Gaucher disease.

Authors:  D Elstein; G M Cohn; N Wang; M Djordjevic; C Brutaru; A Zimran
Journal:  Blood Cells Mol Dis       Date:  2010-08-19       Impact factor: 3.039

3.  Bone ultrasonometry, bone density, and turnover markers in type 1 Gaucher disease.

Authors:  Carmelo Erio Fiore; Rita Barone; Pietra Pennisi; Vito Pavone; Stefania Riccobene
Journal:  J Bone Miner Metab       Date:  2002       Impact factor: 2.626

Review 4.  Intercellular cross-talk among bone cells: new factors and pathways.

Authors:  Natalie A Sims; Nicole C Walsh
Journal:  Curr Osteoporos Rep       Date:  2012-06       Impact factor: 5.096

5.  IL-6 receptor inhibition positively modulates bone balance in rheumatoid arthritis patients with an inadequate response to anti-tumor necrosis factor therapy: biochemical marker analysis of bone metabolism in the tocilizumab RADIATE study (NCT00106522).

Authors:  Morten A Karsdal; Georg Schett; Paul Emery; Olivier Harari; Inger Byrjalsen; Andy Kenwright; Anne C Bay-Jensen; Adam Platt
Journal:  Semin Arthritis Rheum       Date:  2012-03-06       Impact factor: 5.532

Review 6.  Guidance on the use of miglustat for treating patients with type 1 Gaucher disease.

Authors:  Neal J Weinreb; John A Barranger; Joel Charrow; Gregory A Grabowski; Henry J Mankin; Pramod Mistry
Journal:  Am J Hematol       Date:  2005-11       Impact factor: 10.047

7.  Markers of bone turnover in Gaucher disease: modeling the evolution of bone disease.

Authors:  L van Dussen; P Lips; V E Everts; N Bravenboer; I D C Jansen; J E M Groener; M Maas; J A K Blokland; J M F G Aerts; C E M Hollak
Journal:  J Clin Endocrinol Metab       Date:  2011-05-04       Impact factor: 5.958

Review 8.  Targeting the RANK/RANKL/OPG signaling pathway: a novel approach in the management of osteoporosis.

Authors:  Neveen A T Hamdy
Journal:  Curr Opin Investig Drugs       Date:  2007-04

9.  Roles of specific cytokines in bone remodeling and hematopoiesis in Gaucher disease.

Authors:  Makoto Yoshino; Yoriko Watanabe; Yasuyuki Tokunaga; Eimiei Harada; Chieko Fujii; Sanae Numata; Masaru Harada; Asako Tajima; Hiroyuki Ida
Journal:  Pediatr Int       Date:  2007-12       Impact factor: 1.524

10.  Skeletal complications of Gaucher disease.

Authors:  D W Stowens; S L Teitelbaum; A J Kahn; J A Barranger
Journal:  Medicine (Baltimore)       Date:  1985-09       Impact factor: 1.889

View more
  5 in total

1.  Actual reason for bone fractures in the case of a patient followed-up with the osteogenesis imperfecta: Gaucher's Disease.

Authors:  Ufuk Demirci; Ahmet Çizmecioglu; Ismet Aydogdu
Journal:  Clin Cases Miner Bone Metab       Date:  2017-12-27

Review 2.  Gaucher disease: the role of the specialist on metabolic bone diseases.

Authors:  Laura Masi; Maria Luisa Brandi
Journal:  Clin Cases Miner Bone Metab       Date:  2015-10-26

3.  The influence of genetic variability and proinflammatory status on the development of bone disease in patients with Gaucher disease.

Authors:  Javier Gervas-Arruga; Jorge Javier Cebolla; Ignacio de Blas; Mercedes Roca; Miguel Pocovi; Pilar Giraldo
Journal:  PLoS One       Date:  2015-05-15       Impact factor: 3.240

4.  Gene variants of osteoprotegerin, estrogen-, calcitonin- and vitamin D-receptor genes and serum markers of bone metabolism in patients with Gaucher disease type 1.

Authors:  Anca Zimmermann; Radu A Popp; Heidi Rossmann; Simona Bucerzan; Ioana Nascu; Daniel Leucuta; Matthias M Weber; Paula Grigorescu-Sido
Journal:  Ther Clin Risk Manag       Date:  2018-10-24       Impact factor: 2.423

5.  TRAP5b and RANKL/OPG Predict Bone Pathology in Patients with Gaucher Disease.

Authors:  Margarita Ivanova; Julia Dao; Lauren Noll; Jacqueline Fikry; Ozlem Goker-Alpan
Journal:  J Clin Med       Date:  2021-05-20       Impact factor: 4.241

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.